📷 Image: Wikimedia Commons / Kristoferb (talk)
Health
Maharashtra FDA revokes Cipla Pune facility's drug licences, seizes Rs 11.11 lakh stock
✍️ Mid-Day
🗓 28 Aug 2026, 11:17 PM
👁 2
The Maharashtra state Food and Drug Administration has cancelled the drug sale licences of Cipla’s manufacturing unit in Pune, citing regulatory violations, and has confiscated stock valued at Rs 11.11 lakh.
The Maharashtra Food and Drug Administration (FDA) has taken decisive action against Cipla’s drug‑manufacturing facility in Pune, revoking its licences to sell pharmaceutical products. The move follows a detailed inspection that uncovered multiple regulatory breaches at the plant.
Authorities reported that the violations pertained to manufacturing practices, documentation and storage standards, prompting the agency to seize stock worth approximately Rs 11.11 lakh. The seized inventory includes finished drug batches that were deemed non‑compliant with safety norms.
The FDA’s statement emphasized that the enforcement is part of its ongoing effort to ensure that medicines marketed in the state meet stringent quality criteria. Cipla has been asked to address the deficiencies before any future licence applications can be considered. The action underscores the regulator’s commitment to safeguarding public health in Maharashtra.
Authorities reported that the violations pertained to manufacturing practices, documentation and storage standards, prompting the agency to seize stock worth approximately Rs 11.11 lakh. The seized inventory includes finished drug batches that were deemed non‑compliant with safety norms.
The FDA’s statement emphasized that the enforcement is part of its ongoing effort to ensure that medicines marketed in the state meet stringent quality criteria. Cipla has been asked to address the deficiencies before any future licence applications can be considered. The action underscores the regulator’s commitment to safeguarding public health in Maharashtra.